![Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update- Product Image](http://www.researchandmarkets.com/product_images/12392/12392728_500px_jpg/hereditary_angioedema_drugs.jpg)
1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, such as the abdomen or face. Symptoms include severe abdominal pain and cramping, dehydration, diarrhea and shock, hoarse voice, difficulty swallowing and difficulty breathing. Treatment includes medications, such as epinephrine, antihistamines, and corticosteroids.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 4, 3, 4, 10, 3 and 1 respectively.
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development
- ADARx Pharmaceuticals Inc
- Astria Therapeutics Inc
- Attune Pharmaceuticals
- BioMarin Pharmaceutical Inc
- Bioviz Technologies Pvt Ltd
- Bridge Medicines LLC
- CAMP4 Therapeutics Corp
- CSL Ltd
- Intellia Therapeutics Inc
- Ionis Pharmaceuticals Inc
- Kalvista Pharmaceuticals Inc
- Octapharma AG
- Pharming Group NV
- Pharvaris NV
- Ractigen Therapeutics Inc
- Spark Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Verseon Corp
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drug Profiles
- ADX-324 - Drug Profile
- Product Description
- Mechanism Of Action
- ATN-035 - Drug Profile
- Product Description
- Mechanism Of Action
- ATN-249 - Drug Profile
- Product Description
- Mechanism Of Action
- BMN-331 - Drug Profile
- Product Description
- Mechanism Of Action
- C1 esterase inhibitor (human) - Drug Profile
- Product Description
- Mechanism Of Action
- C1 esterase inhibitor (human) - Drug Profile
- Product Description
- Mechanism Of Action
- conestat alfa - Drug Profile
- Product Description
- Mechanism Of Action
- donidalorsen sodium - Drug Profile
- Product Description
- Mechanism Of Action
- garadacimab - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Hereditary Angioedema - Drug Profile
- Product Description
- Mechanism Of Action
- Haegarda - Drug Profile
- Product Description
- Mechanism Of Action
- IONIS-PKKRx - Drug Profile
- Product Description
- Mechanism Of Action
- KV-998052 - Drug Profile
- Product Description
- Mechanism Of Action
- KV-998054 - Drug Profile
- Product Description
- Mechanism Of Action
- KV-998086 - Drug Profile
- Product Description
- Mechanism Of Action
- KVD-998083 - Drug Profile
- Product Description
- Mechanism Of Action
- lanadelumab - Drug Profile
- Product Description
- Mechanism Of Action
- NTLA-2002 - Drug Profile
- Product Description
- Mechanism Of Action
- Oligonucleotides to Activate SERPING1 for Hereditary Angioedema (HAE) - Drug Profile
- Product Description
- Mechanism Of Action
- OTL-105 - Drug Profile
- Product Description
- Mechanism Of Action
- PHVS-416 - Drug Profile
- Product Description
- Mechanism Of Action
- PHVS-719 - Drug Profile
- Product Description
- Mechanism Of Action
- RAG-12 - Drug Profile
- Product Description
- Mechanism Of Action
- sebetralstat - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit Factor XII for Hereditary Angioedema and Inflammation - Drug Profile
- Product Description
- Mechanism Of Action
- STAR-0215 - Drug Profile
- Product Description
- Mechanism Of Action
- VE-4062 - Drug Profile
- Product Description
- Mechanism Of Action
- VE-4666 - Drug Profile
- Product Description
- Mechanism Of Action
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Product Development Milestones
- Featured News & Press Releases
- Nov 21, 2022: Takeda receives prestigious Prix Galien Canada Innovative Product Award for TAKHZYRO (lanadelumab)
- Nov 14, 2022: Intellia Therapeutics to present updated interim clinical data from ongoing phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema at the 2022 ACAAI Annual Scientific Meeting
- Nov 13, 2022: Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
- Nov 12, 2022: Intellia Therapeutics presents new interim data from first-in-human study of NTLA-2002 for the treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
- Nov 07, 2022: Astria Therapeutics to present STAR-0215 modeling and simulation data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting
- Oct 31, 2022: KalVista Pharmaceuticals announces positive phase 1 data for orally disintegrating tablet formulation of sebetralstat for use in hereditary angioedema
- Oct 19, 2022: KalVista Pharmaceuticals announces publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
- Oct 07, 2022: KalVista Pharmaceuticals presents new patient-centric data at 2022 HAEi Global Leadership Workshop
- Oct 05, 2022: U.S. Food and Drug Administration accepts Takeda’s Supplemental Biologics License Application for use of TAKHZYRO (lanadelumab-flyo) to prevent hereditary angioedema (HAE) attacks in children 2 years of age and older
- Sep 30, 2022: Astria Therapeutics to host virtual R&D Day: update on STAR-0215 and its clinical development
- Sep 16, 2022: Intellia Therapeutics announces positive interim clinical data for its second systemically delivered investigational CRISPR candidate, NTLA-2002 for the treatment of hereditary angioedema (HAE)
- Sep 16, 2022: Intellia Therapeutics to present interim clinical data from ongoing phase 1/2 study of NTLA-2002 for the treatment of hereditary angioedema at the 2022 Bradykinin Symposium
- Sep 16, 2022: Intellia Therapeutics announces upcoming investor event to present interim clinical data from ongoing first-in-human studies of NTLA-2002 on September 16, 2022
- Sep 01, 2022: Intellia Therapeutics receives U.S. FDA orphan drug designation for NTLA-2002, an investigational CRISPR therapy for the treatment of Hereditary Angioedema
- Aug 23, 2022: KalVista Pharmaceuticals announces initiation of KONFIDENT-S open label extension study for sebetralstat in hereditary angioedema
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by ADARx Pharmaceuticals Inc, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Astria Therapeutics Inc, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Attune Pharmaceuticals, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by BioMarin Pharmaceutical Inc, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Bioviz Technologies Pvt Ltd, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Bridge Medicines LLC, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CAMP4 Therapeutics Corp, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by CSL Ltd, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Intellia Therapeutics Inc, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ionis Pharmaceuticals Inc, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Kalvista Pharmaceuticals Inc, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Octapharma AG, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharming Group NV, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Pharvaris NV, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Ractigen Therapeutics Inc, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Spark Therapeutics Inc, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline by Verseon Corp, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Dormant Projects, 2022
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Discontinued Products, 2022
- Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ADARx Pharmaceuticals Inc
- Astria Therapeutics Inc
- Attune Pharmaceuticals
- BioMarin Pharmaceutical Inc
- Bioviz Technologies Pvt Ltd
- Bridge Medicines LLC
- CAMP4 Therapeutics Corp
- CSL Ltd
- Intellia Therapeutics Inc
- Ionis Pharmaceuticals Inc
- Kalvista Pharmaceuticals Inc
- Octapharma AG
- Pharming Group NV
- Pharvaris NV
- Ractigen Therapeutics Inc
- Spark Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Verseon Corp
